Feb 26, 2020 / 03:00PM GMT
Danielle Joy Antalffy - SVB Leerink LLC, Research Division - MD of Medical Supplies & Devices and Senior Analyst
All right. Good morning, everyone. Thanks so much for joining us. Sorry about that. I'm Danielle Antalffy, one of the senior medtech analysts here from SVB Leerink. And we are very lucky to have with us Bob White, the Head of the Minimally Invasive Therapies Group at Medtronic. We also have in the audience Ryan Weispfenning and Francesca DeMartino from Investor Relations.
Questions and Answers:
Danielle Joy Antalffy - SVB Leerink LLC, Research Division - MD of Medical Supplies & Devices and Senior AnalystSo we're just going to launch right into a fireside chat format here. So Bob, why don't we start? You guys just reported results last week, MITG, a little bit weaker than you've been looking for. Can you talk about some of the issues that impacted MITG and how -- it sounds like they were pretty transient in nature. What growth would have been ex these issues?
Robert John White - Medtronic plc - Executive VP
Trustpilot
